USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AVID RADIOPHARMACEUTICALS, INC.
City: Philadelphia
State: PA
Zip+4: 19104
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,952,108.00 6
STTR Phase I $500,000.00 1

Award List:

AV1: F-18 Radiopharmaceutical for Imaging Amyloid Plaque

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel M. Skovronsky
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is the development of radiopharmaceuticals for diagnosis of Alzheimer's disease (AD). The project is driven by the hypothesis that in vivo detection of amyloid plaques by positron emission computed tomography imaging (using… More

Radiopharmaceuticals for Imaging Brain Synuclein

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel M. Skovronsky
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is the development of radiopharmaceuticals for diagnosis of Dementia with Lewy Bodies (DLB). DLB is the second most common cause of dementia in the United States; although the disease requires specific pharmacologic… More

Clinical Evaluation of IMPY SPECT for Diagnosis of Alzheimer's

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CALIFORNIA, SAN
Principal Investigator: Daniel M. Skovronsky
Award Amount: $500,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with more than 4.5 million Americans currently suffering from the disease. Clinical management of AD is complicated by lack of effective met hods for early and accurate diagnosis of… More

18F-FP-DTBZ for PET Imaging of Beta Cell Mass in Diabetes

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel M. Skovronsky
Award Amount: $247,050.00
Abstract:
DESCRIPTION (provided by applicant): Both Type I (T1D) and Type 2 (T2D) diabetes share a common pathophysiology - insufficient beta cell mass (BCM) to meet metabolic demands. Unfortunately, advances in diabetes are slowed by a lack of reliable methods to m easure BCM in vivo. The ability to… More

Development of Radiopharmaceuticals for Imaging Brain Tau Pathology

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel M. Skovronsky
Award Amount: $498,812.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with more than 4.5 million Americans currently suffering from the disease. Clinical management of AD is complicated by lack of effective meth ods for early and accurate diagnosis of the… More

18F-AV-133, A Novel Radiopharmaceutical for Differential Diagnosis of Dementia

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $498,750.00
Abstract:
DESCRIPTION (provided by applicant): Dementia, with its most prevalent subforms Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and vascular dementia, is a very substantial medical and societal problem. The emergence of many drugs and drug can didates that interfere with the disease… More

18F-AV-45 PET Imaging of Amyloid in PD with Cognitive Impairment

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel M. Skovronsky
Award Amount: $507,496.00
Abstract:
DESCRIPTION (provided by applicant): Dementia associated with PD (PDD) is common (affecting up to 80% of patients long-term) and highly disabling. Informative biomarkers are urgently needed to understand the pathology of PDD, to improve the early detection of cognitive deficits and to facilitate… More